as 04-18-2025 1:33pm EST
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Founded: | 1983 | Country: | United States |
Employees: | N/A | City: | SEATTLE |
Market Cap: | 133.3M | IPO Year: | N/A |
Target Price: | $13.89 | AVG Volume (30 days): | 950.5K |
Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -1.23 | EPS Growth: | N/A |
52 Week Low/High: | $1.60 - $19.10 | Next Earning Date: | 05-12-2025 |
Revenue: | $1,454,000 | Revenue Growth: | 1.40% |
Revenue Growth (this year): | -48.34% | Revenue Growth (next year): | 1.15% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Woods Lori A | CATX | Director | Mar 31 '25 | Buy | $2.13 | 23,475 | $49,999.40 | 183,460 | |
Graham Juan | CATX | Chief Financial Officer | Mar 28 '25 | Buy | $2.25 | 33,333 | $74,945.92 | 35,354 | |
Williamson Robert F III | CATX | Director | Mar 28 '25 | Buy | $2.21 | 60,337 | $132,151.09 | 70,837 | |
Spoor Johan M. | CATX | Chief Executive Officer | Mar 28 '25 | Buy | $2.23 | 26,676 | $59,672.62 | 59,383 |
CATX Breaking Stock News: Dive into CATX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
MT Newswires
8 days ago
GlobeNewswire
8 days ago
MT Newswires
12 days ago
Zacks
17 days ago
GlobeNewswire
19 days ago
MT Newswires
23 days ago
GlobeNewswire
24 days ago
The information presented on this page, "CATX Perspective Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.